Historial de carrera de Jose Olague
Antiguos cargos conocidos de Jose Olague.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALPHA TEKNOVA, INC. | Director Técnico/Científico/I+D | 01/05/2020 | 01/09/2023 |
| AVINGER, INC. | Corporate Officer/Principal | - | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Formación de Jose Olague.
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| México | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jose Olague
- Experiencia
